A Randomized Phase III Study to Compare Conventional Chemotherapy (CHOEP-14) + Rituximab vs High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation (Mega-CHOEP-21) + Rituximab in Younger Patients With Aggressive NHL
This study compares aggressive conventional therapy (8 courses of rituximab plus CHOEP given
every 2 weeks) with repetitive high-dose therapy (Mega-CHOEP) supplemented with rituximab.
The study question is whether overall survival or progression-free survival is better with
high-dose therapy than with conventional treatment.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
time to treatment failure
Norbert Schmitz, Prof.
German High-Grade Non-Hodgkin's Lymphoma Study Group
Germany: Federal Institute for Drugs and Medical Devices